Meet the Investors

Edward van Wezel | Managing Partner, BioGeneration Ventures

Edward is Managing Partner and co-founder of BGV. Edward started his career as process engineer for Chiron Inc. He subsequently worked in product development and corporate licensing at Johnson & Johnson. Since 2000 he expanded his experience as CEO of several life sciences companies in the Netherlands. He currently serves on the supervisory boards of Azafaros, Scenic Biotech, Confo Therapeutics, TigaTx and Genase Therapeutics. He previously served on the supervisory boards of Progentix Orthobiology (acquired by Nuvasive ), Noviogendix (acquired by MDxHealth), was founding investor and supervisory board member of Acerta Pharma (acquired by Astra Zeneca) and was supervisory board member at Synaffix (sold to Lonza). Edward is also on the board of Mibiton. Edward holds a M.Sc. in chemistry from the University of Utrecht and a M.Sc in Biochemical Engineering from the Delft University of Technology.

About BioGeneration Ventures

BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies.With a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies, BGV manages over €440 million across 5 fund, and invests in areas where true scientific innovations, unmet medical needs, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to progress science and build successful companies and uses its experience to guide progress into clinical trials, leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. BGV operates a joint venture partnership with Forbion. The Company is based in Naarden, The Netherlands. For more information, please visit: http://www.biogenerationventures.com.